- TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
- Choucair K, Morand S, Stanbery L, Edelman G, Dworkin L, Nemunaitis J.
- Cancer Gene Ther. 2020 Apr 28. doi: 10.1038/s41417-020-0174-y. [Epub ahead of print]
- PMID: 32341410
- PubMed abstract
- Source abstract
- Review
- Olaparib for Metastatic Castration-Resistant Prostate Cancer.
- de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M.
- N Engl J Med. 2020 Apr 28. doi: 10.1056/NEJMoa1911440. [Epub ahead of print]
- PMID: 32343890
- PubMed abstract
- Source abstract
- ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy.
- Golan T, Barenboim A, Lubezky N.
- Ann Surg Oncol. 2020 Apr 27. doi: 10.1245/s10434-020-08495-6. [Epub ahead of print]
- PMID: 32342298
- PubMed abstract
- Source abstract
- Research review, Commentary
Original research:
Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
- PMID: 32314163
- PubMed abstract
- Source abstract
- Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
- Talhouet S, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, Bodmer A, Treilleux I, Lang N, Tille JC, Chappuis PO, Buisson A, Giraud S, Lasset C, Bonadona V, Trédan O, Labidi-Galy SI.
- Sci Rep. 2020 Apr 27;10(1):7073. doi: 10.1038/s41598-020-63759-1.
- PMID: 32341426
- PubMed abstract